Rigel Pharmaceuticals, Inc. RI2A.F Stock
Rigel Pharmaceuticals, Inc. Price Chart
Rigel Pharmaceuticals, Inc. RI2A.F Financial and Trading Overview
Rigel Pharmaceuticals, Inc. stock price | 0.86 EUR |
Previous Close | 1.39 EUR |
Open | 1.48 EUR |
Bid | 1.48 EUR x 150000 |
Ask | 1.54 EUR x 150000 |
Day's Range | 1.48 - 1.48 EUR |
52 Week Range | 0.63 - 1.98 EUR |
Volume | 590 EUR |
Avg. Volume | 289 EUR |
Market Cap | 257.29M EUR |
Beta (5Y Monthly) | 0.720422 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.33 EUR |
RI2A.F Valuation Measures
Enterprise Value | 294.77M EUR |
Trailing P/E | N/A |
Forward P/E | -4.9266667 |
PEG Ratio (5 yr expected) | -1.98 |
Price/Sales (ttm) | 2.0570903 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 2.357 |
Enterprise Value/EBITDA | -6.796 |
Trading Information
Rigel Pharmaceuticals, Inc. Stock Price History
Beta (5Y Monthly) | 0.720422 |
52-Week Change | 54.24% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1.98 EUR |
52 Week Low | 0.63 EUR |
50-Day Moving Average | 1.18 EUR |
200-Day Moving Average | 1.19 EUR |
RI2A.F Share Statistics
Avg. Volume (3 month) | 289 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 173.67M |
Float | 142.18M |
Short Ratio | N/A |
% Held by Insiders | 1.43% |
% Held by Institutions | 69.91% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -35.70% |
Operating Margin (ttm) | -35.57% |
Gross Margin | 54.03% |
EBITDA Margin | -34.67% |
Management Effectiveness
Return on Assets (ttm) | -20.39% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 125.08M EUR |
Revenue Per Share (ttm) | 0.72 EUR |
Quarterly Revenue Growth (yoy) | 55.80% |
Gross Profit (ttm) | 53.72M EUR |
EBITDA | -43376000 EUR |
Net Income Avi to Common (ttm) | -44664000 EUR |
Diluted EPS (ttm) | -0.23 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 58.66M EUR |
Total Cash Per Share (mrq) | 0.34 EUR |
Total Debt (mrq) | 106.14M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 2.35 |
Book Value Per Share (mrq) | -0.14 |
Cash Flow Statement
Operating Cash Flow (ttm) | -52195000 EUR |
Levered Free Cash Flow (ttm) | -52387000 EUR |
Profile of Rigel Pharmaceuticals, Inc.
Country | Germany |
State | CA |
City | South San Francisco |
Address | 611 Gateway Blvd |
ZIP | 94080 |
Phone | 650 624 1100 |
Website | https://www.rigel.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 155 |
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company was incorporated in 1996 and is headquartered in South San Francisco, California.
Q&A For Rigel Pharmaceuticals, Inc. Stock
What is a current RI2A.F stock price?
Rigel Pharmaceuticals, Inc. RI2A.F stock price today per share is 0.86 EUR.
How to purchase Rigel Pharmaceuticals, Inc. stock?
You can buy RI2A.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Rigel Pharmaceuticals, Inc.?
The stock symbol or ticker of Rigel Pharmaceuticals, Inc. is RI2A.F.
Which industry does the Rigel Pharmaceuticals, Inc. company belong to?
The Rigel Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Rigel Pharmaceuticals, Inc. have in circulation?
The max supply of Rigel Pharmaceuticals, Inc. shares is 176.86M.
What is Rigel Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Rigel Pharmaceuticals, Inc. PE Ratio is now.
What was Rigel Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Rigel Pharmaceuticals, Inc. EPS is -0.1 EUR over the trailing 12 months.
Which sector does the Rigel Pharmaceuticals, Inc. company belong to?
The Rigel Pharmaceuticals, Inc. sector is Healthcare.